Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045526 | 1.00 | HTR6 (0.58) | HTR6CHRM2CHRM4CHRM1SLC6A2 | |
| Hydrochloric Acid SCHEMBL2223844 | 0.98 | HTR6 (0.60) | HTR6CHRM2CHRM4CHRM1SLC6A2 | |
| SCHEMBL4233870 | 0.86 | HTR6 (0.45) | HTR6HTR2C | |
| Hydrochloric Acid SCHEMBL6644060 | 0.85 | HTR6 (0.47) | HTR6HTR2C | |
| SCHEMBL18204707 | 0.84 | HTR6 (0.42) | HTR6HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL18204598 | 0.82 | HTR6 (0.44) | HTR6HTR2AHTR2CHTR2B | |
| SCHEMBL11959914 | 0.78 | HTR6 (0.43) | HTR6 | |
| SCHEMBL23899062 | 0.78 | HTR6 (0.58) | HTR6HTR2AHTR2C | |
| SCHEMBL13836022 | 0.78 | HTR6 (0.47) | HTR6CHRM2CHRM4CHRM1SLC6A2 | |
| SCHEMBL30369327 | 0.78 | HTR6 (0.58) | HTR6HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492187-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20230147170-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4125892-A1 | FACTOR XI ACTIVATION INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202254-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-8765779-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2516445-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Cephalon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011087712-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492187-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | HTR6 4391/4885CHRM2 4434/4885CHRM4 4767/4885 |
| US-20230147170-A1 | FACTOR XI ACTIVATION INHIBITORS | F11, TFPI, F13B | HTR6 4391/4885CHRM2 4434/4885CHRM4 4767/4885 |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP3A43, CYP3A7, CYP2C19 | HTR6 537/4885CHRM2 392/4885CHRM4 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.